Ocular Graft-versus-Host Disease after Hematopoietic Cell Transplantation: Expert Review from the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and Transplant Complications Working Party of the European Society of Blood and Marrow Transplantation.

Inamoto, Yoshihiro; Valdés-Sanz, Nuria; Ogawa, Yoko; Alves, Monica; Berchicci, Luigi; Galvin, John; Greinix, Hildegard; Hale, Gregory A; Horn, Biljana; Kelly, Debra; Liu, Hien; Rowley, Scott; Schoemans, Helene; Shah, Ami; Lupo Stanghellini, Maria Teresa; Agrawal, Vaibhav; Ahmed, Ibrahim; Ali, Asim; Bhatt, Neel; Byrne, Michael; ... (2018). Ocular Graft-versus-Host Disease after Hematopoietic Cell Transplantation: Expert Review from the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and Transplant Complications Working Party of the European Society of Blood and Marrow Transplantation. Biology of blood and marrow transplantation, 25(2), e46-e54. Elsevier 10.1016/j.bbmt.2018.11.021

Text 1-s2.0-S1083879118307547-main.pdf - Published Version Restricted to registered users only Available under License Publisher holds Copyright. Download (488kB)

Ocular graft-versus-host disease (GVHD) occurs in more than one-half of patients who develop chronic GVHD after allogeneic hematopoietic cell transplantation (HCT), causing prolonged morbidity that affects activities of daily living and quality of life. Here we provide an expert review of ocular GVHD in a collaboration between transplantation physicians and ophthalmologists through the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and the Transplant Complications Working Party of the European Society of Blood and Marrow Transplantation. Recent updates in ocular GVHD regarding pathophysiology, preclinical models, risk factors, prevention, screening, diagnosis, response criteria, evaluation measures, and treatment are discussed. Ocular GVHD involves at least 3 biological processes: lacrimal gland dysfunction, meibomian gland dysfunction, and corneoconjunctival inflammation. Preclinical models have identified several novel pathogenic mechanisms, including the renin angiotensin system and endoplasmic reticulum stress signaling, which can be targeted by therapeutic agents. Numerous studies have identified reliable tests for establishing diagnosis and response assessment of ocular GVHD. The efficacy of systemic and topical treatment for ocular GVHD is summarized. It is important that all health professionals caring for HCT recipients have adequate knowledge of ocular GVHD to provide optimal care.

Interest & Impact

Downloads

3 since deposited on 31 Jan 2019
0 in the past 12 months

Citations

5 Citations in Web of Science ®
6 Citations in Scopus

Search

in Google Scholar™

Services

Actions (login required)

Edit item

Actions (login required)

Edit item